BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vetsika EK, Koukos A, Kotsakis A. Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells 2019;8:E1647. [PMID: 31847487 DOI: 10.3390/cells8121647] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino KI. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. Cancer Immunol Immunother 2023;72:851-64. [PMID: 36104597 DOI: 10.1007/s00262-022-03293-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Decraene B, Vanmechelen M, Clement P, Daisne JF, Vanden Bempt I, Sciot R, Garg AD, Agostinis P, De Smet F, De Vleeschouwer S. Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. Cancer Med 2023. [PMID: 36776000 DOI: 10.1002/cam4.5681] [Reference Citation Analysis]
3 Kapetanakis NI, Busson P. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies. Front Immunol 2023;14:1145268. [PMID: 36817445 DOI: 10.3389/fimmu.2023.1145268] [Reference Citation Analysis]
4 Ren Y, Bäcker H, Müller M, Kienzle A. The role of myeloid derived suppressor cells in musculoskeletal disorders. Front Immunol 2023;14:1139683. [PMID: 36936946 DOI: 10.3389/fimmu.2023.1139683] [Reference Citation Analysis]
5 Navin I, Parihar R. Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors. NK Cells in Cancer Immunotherapy: Successes and Challenges 2023. [DOI: 10.1016/b978-0-12-822620-9.00011-2] [Reference Citation Analysis]
6 Jinna N, Rida P, Su T, Gong Z, Yao S, LaBarge M, Natarajan R, Jovanovic-Talisman T, Ambrosone C, Seewaldt V. The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations. Cells 2022;11. [PMID: 36497078 DOI: 10.3390/cells11233818] [Reference Citation Analysis]
7 Sánchez-león ML, Jiménez-cortegana C, Cabrera G, Vermeulen EM, de la Cruz-merino L, Sánchez-margalet V. The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1050484] [Reference Citation Analysis]
8 Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Mol Cancer 2022;21:189. [PMID: 36175961 DOI: 10.1186/s12943-022-01656-z] [Reference Citation Analysis]
9 Bizymi N, Matthaiou AM, Matheakakis A, Voulgari I, Aresti N, Zavitsanou K, Karasachinidis A, Mavroudi I, Pontikoglou C, Papadaki HA. New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology. J Clin Med 2022;11:5326. [PMID: 36142973 DOI: 10.3390/jcm11185326] [Reference Citation Analysis]
10 Liu T, Gonzalez De Los Santos F, Rinke AE, Fang C, Flaherty KR, Phan SH. B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis. Front Immunol 2022;13:901349. [DOI: 10.3389/fimmu.2022.901349] [Reference Citation Analysis]
11 D. Radosavljevic G, Pantic J, Simovic Markovic B, Arsenijevic N. Modulators of Tumor Angiogenesis: Insights into the Role of Galectin-3 and IL-17 Signaling. Tumor Angiogenesis and Modulators 2022. [DOI: 10.5772/intechopen.102893] [Reference Citation Analysis]
12 Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res 2022. [PMID: 35759090 DOI: 10.1007/s12272-022-01389-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Deng X, Li X, Guo X, Lu Y, Xie Y, Huang X, Lin J, Tan W, Wang C. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia 2022;28:100788. [DOI: 10.1016/j.neo.2022.100788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 Walsh KA, Kastrappis G, Fifis T, Paolini R, Christophi C, Perini MV. SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis. Cancers (Basel) 2022;14:2715. [PMID: 35681695 DOI: 10.3390/cancers14112715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Taeb S, Najafi M. Modulation of the immune system by melatonin; implications for cancer therapy. Int Immunopharmacol 2022;108:108890. [PMID: 35623297 DOI: 10.1016/j.intimp.2022.108890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zheng X, Huang Y, Li K, Luo R, Cai M, Yun J. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies. Viruses 2022;14:1017. [DOI: 10.3390/v14051017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ruan L, Zhang S, Chen X, Liang W, Xie Q. Role of Anti-Angiogenic Factors in the Pathogenesis of Breast Cancer: A Review of Therapeutic Potential. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153956] [Reference Citation Analysis]
18 Exley MA, Garcia S, Zellander A, Zilberberg J, Andrews DW. Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma. J Clin Med 2022;11:1069. [PMID: 35207340 DOI: 10.3390/jcm11041069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Shamshiripour P, Nikoobakht M, Mansourinejad Z, Ahmadvand D, Akbarpour M. A comprehensive update to DC therapy for glioma; a systematic review and meta-analysis. Expert Review of Vaccines. [DOI: 10.1080/14760584.2022.2027759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer 2021;9:e003237. [PMID: 34815355 DOI: 10.1136/jitc-2021-003237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
21 Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. Biofactors 2021. [PMID: 34375483 DOI: 10.1002/biof.1776] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
22 Kadomoto S, Izumi K, Mizokami A. Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. Int J Mol Sci 2021;22:8530. [PMID: 34445235 DOI: 10.3390/ijms22168530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
23 Chen H, Jiang T, Lin F, Guan H, Zheng J, Liu Q, Du B, Huang Y, Lin X. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer. Int Immunopharmacol 2021;99:107929. [PMID: 34343940 DOI: 10.1016/j.intimp.2021.107929] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
24 Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
25 Lan H, Zhang W, Jin K, Liu Y, Wang Z. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv 2020;27:1248-62. [PMID: 32865029 DOI: 10.1080/10717544.2020.1809559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Gillot L, Baudin L, Rouaud L, Kridelka F, Noël A. The pre-metastatic niche in lymph nodes: formation and characteristics. Cell Mol Life Sci 2021;78:5987-6002. [PMID: 34241649 DOI: 10.1007/s00018-021-03873-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
27 Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P. Combinatorial therapy in tumor microenvironment: Where do we stand? Biochim Biophys Acta Rev Cancer 2021;1876:188585. [PMID: 34224836 DOI: 10.1016/j.bbcan.2021.188585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
28 Wang J, Hao JP, Uddin MN, Wu Y, Chen R, Li DF, Xiong DQ, Ding N, Yang JH, Ding XS. Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia. Aging (Albany NY) 2021;13:16445-70. [PMID: 34148032 DOI: 10.18632/aging.203166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zalfa C, Paust S. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. Front Immunol 2021;12:633205. [PMID: 34025641 DOI: 10.3389/fimmu.2021.633205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
30 Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathol Oncol Res 2021;27:1609802. [PMID: 34257622 DOI: 10.3389/pore.2021.1609802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
31 Herrero A, Benedicto A, Romayor I, Olaso E, Arteta B. Inhibition of COX-2 Impairs Colon Cancer Liver Metastasis through Reduced Stromal Cell Reaction. Biomol Ther (Seoul). 2021;. [PMID: 33455946 DOI: 10.4062/biomolther.2020.160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Sugita Y, Yamashita K, Fujita M, Saito M, Yamada K, Agawa K, Watanabe A, Fukuoka E, Hasegawa H, Kanaji S, Oshikiri T, Matsuda T, Nakamura T, Suzuki S, Kakeji Y. CD244+ polymorphonuclear myeloid‑derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model. Oncol Rep 2021;45:106. [PMID: 33907826 DOI: 10.3892/or.2021.8057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Olivares-Hernández A, Figuero-Pérez L, Terán-Brage E, López-Gutiérrez Á, Velasco ÁT, Sarmiento RG, Cruz-Hernández JJ, Miramontes-González JP. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. J Clin Med 2021;10:1919. [PMID: 33925214 DOI: 10.3390/jcm10091919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Wei Q, Singh O, Ekinci C, Gill J, Li M, Mamatjan Y, Karimi S, Bunda S, Mansouri S, Aldape K, Zadeh G. TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. Acta Neuropathol Commun 2021;9:67. [PMID: 33853689 DOI: 10.1186/s40478-021-01163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Kim J, Hong J, Lee J, Fakhraei Lahiji S, Kim Y. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. Journal of Controlled Release 2021;332:109-26. [DOI: 10.1016/j.jconrel.2021.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
36 Jiang H, Zhu M, Guo P, Bi K, Lu Z, Li C, Zhai M, Wang K, Cao Y. Impaired myeloid-derived suppressor cells are associated with recurrent implantation failure: A case-control study. J Reprod Immunol 2021;145:103316. [PMID: 33866110 DOI: 10.1016/j.jri.2021.103316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J, Yu Y. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:653358. [PMID: 33746989 DOI: 10.3389/fimmu.2021.653358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
38 Nezami N, Sanchez CJ, Moon J, Shaikh J, Kokabi N. Cancer Immunology and Immuno-Oncology (Innate vs. Adaptive Cell Immunity). Digestive Disease Interventions 2021;05:032-049. [DOI: 10.1055/s-0040-1721799] [Reference Citation Analysis]
39 Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomedicine 2021;16:1631-61. [PMID: 33688183 DOI: 10.2147/IJN.S290346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
40 Ren Y, Dong X, Zhao H, Feng J, Chen B, Zhou Y, Peng Y, Zhang L, Zhou Q, Li Y, Wu M, He Y. Myeloid-derived suppressor cells improve corneal graft survival through suppressing angiogenesis and lymphangiogenesis. Am J Transplant 2021;21:552-66. [PMID: 32892499 DOI: 10.1111/ajt.16291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
41 Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol 2021;361:104295. [PMID: 33508529 DOI: 10.1016/j.cellimm.2021.104295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
42 Fenselau C, Ostrand-Rosenberg S. Molecular cargo in myeloid-derived suppressor cells and their exosomes. Cell Immunol 2021;359:104258. [PMID: 33338939 DOI: 10.1016/j.cellimm.2020.104258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
43 Iwamoto H, Izumi K, Mizokami A. Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis? Int J Mol Sci 2020;21:E9328. [PMID: 33297571 DOI: 10.3390/ijms21239328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
44 Liu BQ, Bao ZY, Zhu JY, Liu H. Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment. Oncol Lett 2021;21:47. [PMID: 33281958 DOI: 10.3892/ol.2020.12308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
46 Siebert N, Zumpe M, von Lojewski L, Troschke-Meurer S, Marx M, Lode HN. Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO. Oncoimmunology 2020;9:1836768. [PMID: 33150046 DOI: 10.1080/2162402X.2020.1836768] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Hofman P. New insights into the interaction of the immune system with non-small cell lung carcinomas. Transl Lung Cancer Res 2020;9:2199-213. [PMID: 33209644 DOI: 10.21037/tlcr-20-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Gordon B, Gadi VK. The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines (Basel) 2020;8:E529. [PMID: 32937885 DOI: 10.3390/vaccines8030529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
49 Zarobkiewicz M, Kowalska W, Chocholska S, Tomczak W, Szymańska A, Morawska I, Wojciechowska A, Bojarska-Junak A. High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. Cancers (Basel) 2020;12:E2614. [PMID: 32937740 DOI: 10.3390/cancers12092614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
50 Qin XS, Zhang CL, Huang ZS. Influence of tumor microenvironment on angiogenesis in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 493-500 [DOI: 10.11569/wcjd.v28.i12.493] [Reference Citation Analysis]
51 Jin S, Yang Z, Hao X, Tang W, Ma W, Zong H. Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment. Biomark Res 2020;8:21. [PMID: 32551121 DOI: 10.1186/s40364-020-00201-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
52 Basse C, Swalduz A, Levra MG, Girard N, Remon J, Moro-Sibilot D. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. Bull Cancer 2020;107:779-91. [PMID: 32532420 DOI: 10.1016/j.bulcan.2020.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Toor SM, Khalaf S, Murshed K, Abu Nada M, Elkord E. Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages. J Immunol Res 2020;2020:9678168. [PMID: 32626789 DOI: 10.1155/2020/9678168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Mi Y, Guo N, Luan J, Cheng J, Hu Z, Jiang P, Jin W, Gao X. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment. Front Immunol 2020;11:737. [PMID: 32391020 DOI: 10.3389/fimmu.2020.00737] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
55 Papaxenopoulou LA, Zhao G, Khailaie S, Katsoulis-dimitriou K, Schmitz I, Medina E, Hatzikirou H, Meyer-hermann M. Chronic Staphylococcus aureus infection is cured by theory-driven therapy.. [DOI: 10.1101/2020.01.17.910786] [Reference Citation Analysis]